All In Biotech

Drug Trial Radar · NCT02100813

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

May 2014

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Apr 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle

Conditions

  • Actinic Keratosis

Interventions

  • LEO 43204Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Experiencing a Dose-limiting Toxicity (DLT)Time frame: From Day 1 up to and including Day 8
  2. Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) Lesion CountTime frame: From baseline to Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gwinnett Clinical Research Center, Inc.

    Snellville, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.